DOCSLIB.ORG

Abstracts from the 50Th European Society of Human Genetics Conference: Oral Presentations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstracts from the 50Th European Society of Human Genetics Conference: Oral Presentations European Journal of Human Genetics (2019) 26:3–112 https://doi.org/10.1038/s41431-018-0249-5 ABSTRACT Abstracts from the 50th European Society of Human Genetics Conference: Oral Presentations Copenhagen, Denmark, May 27–30, 2017 Published online: 1 October 2018 © European Society of Human Genetics 2018 The ESHG 2017 marks the 50th Anniversary of the first ESHG Conference which took place in Copenhagen in 1967. Additional information about the event may be found on the conference website: https://2017.eshg.org/ Sponsorship: Publication of this supplement is sponsored by the European Society of Human Genetics. All authors were asked to address any potential bias in their presentation and to declare any competing financial interests. These disclosures are listed at the end of each presentation. Contributions of up to EUR 10 000 (ten thousand euros, or equivalent value in kind) per year per company are considered "modest". Contributions above EUR 10 000 per year are considered "significant". Plenary Sessions By 1988 it had become clear that something more was needed if the ESHG was to become a significant force in 1234567890();,: 1234567890();,: developing a European human genetics community. Revo- PL1 lutionary moves culminated at the meeting in Leuven in 50 years of ESHG 1991 where a rotating president and officers were elected, and statutes adopted formally incorporating the society PL1.1 under Belgian law. The society’s journal, the European A brief history of how we got here Journal of Human Genetics, was established shortly after- wards and the modern ESHG was born. We now have an A. Read annual turnover of over 2 million euros, professional administration through Jerome del Picchia and his team at Manchester, United Kingdom the Vienna Medical Academy, and an important voice in European and international developments in human genet- This year the European Society of Human Genetics ics. Jan Mohr (who died in 2009) might have mixed feelings celebrates the 50th anniversary of its first meeting, held here about some of these developments but surely he would in Copenhagen in 1967. I have been asked, on behalf of the agree that this 2017 meeting is the best human genetics Board and Executive of the Society, to start off this year’s conference ever. conference with a brief look back at how we came to be here. In doing this I have drawn heavily on the historical A. Read: None. material assembled by Professor Peter Harper, whose arti- cles should be consulted for more detail. PL1.2 The story of the ESHG is a story of two halves. The first How will the present time in genetics be 24 years, up to 1991, were dominated by one man, Professor remembered? Jan Mohr of Copenhagen. When he agreed with a small group of colleagues to start a European Society of Human H. Brunner1,2 Genetics his vision was of a stripped-down organisation with minimal administrative tasks. There were no elected officers, 1Department of Human Genetics Radboud UMC, Nijmegen, just a permanent secretary (himself for all those years) and Netherlands, 2Dept of Clinical Genetics, Maastricht UMC, an unchanging 20-member Board. Virtually their only Maastricht, Netherlands function was to nominate somebody each year to organise a symposium on some aspect of human genetics. The society At 50 years, the Society of Human Genetics has con- gave no financial support for this - it hardly could, with only fidently assumed its current position as a pillar of modern around 200 members whose subscription was $7. medicine. Is ours a special time? Have we reached the 4 high-point of Human Genetics? I don’t think that the techniques for mosaic situations, long read sequencing for history of human genetics ends here at all. Rather, it repetitive elements and other genomic dark matter, and seems that fundamental change is still very much in the whole genome sequencing to capture smaller genomic air. First, let’s celebrate that after more than 100 years, the rearrangements. All of these will come. Still, reading the battle between the Mendelians and Biometricians has genome does not equal understanding it. Fortunately, finally ended. And it is a draw. Mendelian rare conditions Functional Genomics is about to come of age, now that mainly reflect gene disruptions subject to strong selective the groundwork has been done with the Hapmap, forces, whereas common complex disease largely reflects ENCODE and Blueprint projects. The future of Human common polygenic regulatory variation of gene activity. Genomics will be radically different as we start to study Sometimes these mix, as for the major neurodevelop- Traits rather than States, and this at the single cell level mental disorders: Intellectual disability, Autism, and and in real time. Multi-omics approaches will arrive soon, Schizophrenia are mostly due to a mix of polygenic and as will innovative gene therapy approaches. The future de novo single gene variants. The Mendelian forms being may turn out much more surprising and informative than associated with lower IQ. As Galton predicted in the 19th any of us can now predict. century, height is generally polygenic and Peter Vis- scher’s work has used this data to show that most of the H. Brunner: None. heritability is not missing but undetected, because the effects of individual loci are too small to pass stringent PL1.3 significance tests. Work from Sardinia shows that some of The Future: Solved Problems and Persisting the alleles that confer short stature affect known Mende- Challenges lian genes, which have drifted up to appreciable fre- quencies in this population to create the well-known A. Visel1,2,3 island effect on height. After a period of frenzied activity following the invention of next generation sequencing, the 1Lawrence Berkeley National Laboratory, Berkeley, CA, era of monogenic disease gene discovery has passed its United States, 2DOE Joint Genome Institute, Walnut Creek, peak. At the same time, our ability to see pathogenic CA, United States, 3University of California, Merced, CA, variation rather than infer it, is fundamentally changing United States medicine and our societies. Rare diseases have become a recognized part of medicine, not just curiosities. One such Groundbreaking discoveries by individual researchers, area where gene-based discoveries are changing medicine disruptive technological advancements, and massive-scale fast is cancer therapy. The understanding of the gene data collection efforts by large research consortia have composition of the Philadelphia chromosome led to the fundamentally transformed the field of human genetics. The first targeted cancer drug, Imatinib. Other examples fol- introduction of powerful data generation and analysis lowed such as EGFR mutations in lung cancer. Soon, all techniques fueled the emergence and rapid growth of the womenwithbreastandovariancancerwillbetestedfor field of genomics as a data-driven science. Researchers now BRCA1 and BRCA2 mutations, to guide their therapy. routinely apply genomic approaches to resolve the genetic Similar testing could happen for male patients with basis of human diseases in ways that were unimaginable prostate cancer. All this will lead to an enormous increase just a few decades ago. Extrapolating from the mind- in the detection of people with genetic predisposition for boggling pace of progress to date, I will attempt to speculate cancers, which constitutes an interesting example of how about the future of human genetics and genomics in the Molecular Pathology and Mendelian predisposition decades ahead. Specifically, I will discuss ways in which genetics come together. Work by Ségolene Ayme and many current challenges will likely become resolved others has led to the recent launch of the European through foreseeable technological improvements. More Reference Networks whose purpose is to improve diag- importantly, I will describe problems that are expected to nosisandcareforrarediseasespatientsacrossEurope. present persistent conceptual challenges. In particular, I will NIPT represents another major triumph for the power of discuss the continued conquest to decipher the vast non- next generation sequencing technology. It is almost coding portion of the human genome, our current difficul- incomprehensible how NIPT seemed such a distant goal ties in understanding its function, and barriers to identifying for so many years. The diagnostic rate of exome connections between non-coding sequence changes and sequencing and microarrays is between 20 and 60% for human disease. most diagnostic situations where Mendelian disease is sought. This experience underlines that the genome is not A. Visel: None. entirely readable yet. Progress requires single cell Abstracts from the 50th European Society of Human Genetics Conference: Oral. 5 PL2 E. Klopocki: None. D.G. Lupiáñez: None. S. Mundlos: What’s New? Highlights Session None. PL2.1 PL2.2 Enhancer composition and dosage control Quantifying the impact of rare coding variation developmental gene expression across the phenotypic spectrum A. J. Will1,2, G. Cova1,2, M. Osterwalder3, W. Chan1,2, N. Brieske1, A. Ganna1, F. K. Satterstrom1, S. Zekavat1, I. Das2, J. Alfoldi1,M.I. A. Visel3, E. Klopocki4, D. G. Lupiáñez1,2, S. Mundlos1,2 Kurki1, W. K. Thompson3, A. Byrnes1, K. J. Karczewski1, M. A. Rivas4, C. Churchhouse1, J. Flannick1, D. MacArthur1, M. J. Daly1,P.F. 1Max Planck Institute for Molecular Genetics, RG Devel- Sullivan5, J. C. Florez1, A. Palotie6, A. E. Locke7, A. Børglum8, opment and Disease, Berlin, Germany, 2Institute for Med- S. Kathiresan1, B. M. Neale1 ical
Load more

Recommended publications
  • Genetic Analysis of Retinopathy in Type 1 Diabetes
    Genetic Analysis of Retinopathy in Type 1 Diabetes by Sayed Mohsen Hosseini A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto © Copyright by S. Mohsen Hosseini 2014 Genetic Analysis of Retinopathy in Type 1 Diabetes Sayed Mohsen Hosseini Doctor of Philosophy Institute of Medical Science University of Toronto 2014 Abstract Diabetic retinopathy (DR) is a leading cause of blindness worldwide. Several lines of evidence suggest a genetic contribution to the risk of DR; however, no genetic variant has shown convincing association with DR in genome-wide association studies (GWAS). To identify common polymorphisms associated with DR, meta-GWAS were performed in three type 1 diabetes cohorts of White subjects: Diabetes Complications and Control Trial (DCCT, n=1304), Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR, n=603) and Renin-Angiotensin System Study (RASS, n=239). Severe (SDR) and mild (MDR) retinopathy outcomes were defined based on repeated fundus photographs in each study graded for retinopathy severity on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Multivariable models accounted for glycemia (measured by A1C), diabetes duration and other relevant covariates in the association analyses of additive genotypes with SDR and MDR. Fixed-effects meta- analysis was used to combine the results of GWAS performed separately in WESDR, ii RASS and subgroups of DCCT, defined by cohort and treatment group. Top association signals were prioritized for replication, based on previous supporting knowledge from the literature, followed by replication in three independent white T1D studies: Genesis-GeneDiab (n=502), Steno (n=936) and FinnDiane (n=2194).
    [Show full text]
  • Genome-Wide Characterization of PRE-1 Reveals a Hidden Evolutionary Relationship Between Suidae and Primates
    bioRxiv preprint doi: https://doi.org/10.1101/025791; this version posted August 31, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genome-wide characterization of PRE-1 reveals a hidden evolutionary relationship between suidae and primates Hao Yu1,, Qingyan Wu1, Jing Zhag1, Ying zhang1, Chao Lu1, Yunyun Cheng1, Zhihui Zhao1, Andreas Windemuth3, Di Liu2,, Linlin Hao1 1 College of Animal Science, Jilin University, Changchun 130062, China 2 Heilongjiang Academy of Agricultural Sciences, Harbin 150086, China 3 Abcam, Firefly BioWorks Inc, United States Corresponding author: Linlin Hao ([email protected]); Di liu ([email protected]); Andreas Windemuth ([email protected]) Abstract We identified and characterized a free PRE-1 element inserted into the promoter region of the porcine IGFBP7 gene whose integration mechanisms into the genome, including copy number, distribution preferences, capacity to exonize and phyloclustering pattern are similar to that of the primate Alu element. 98% of these PRE-1 elements also contain two conserved internal AluI restriction enzyme recognition sites, and the RNA structure of PRE1 can be folded into a two arms model like the Alu RNA structure. It is more surprising that the length of the PRE-1 fragments is nearly the same in 20 chromosomes and positively correlated to its fracture site frequency. All of these fracture sites are close to the mutation hot spots of PRE-1 families, and most of these hot spots are located in the non-complementary fragile regions of the PRE-1 RNA structure.
    [Show full text]
  • Download (PDF)
    ANALYTICAL SCIENCES NOVEMBER 2020, VOL. 36 1 2020 © The Japan Society for Analytical Chemistry Supporting Information Fig. S1 Detailed MS/MS data of myoglobin. 17 2 ANALYTICAL SCIENCES NOVEMBER 2020, VOL. 36 Table S1 : The protein names (antigens) identified by pH 2.0 solution in the eluted-fraction. These proteins were identified one or more out of six analyses. Accession Description P08908 5-hydroxytryptamine receptor 1A OS=Homo sapiens GN=HTR1A PE=1 SV=3 - [5HT1A_HUMAN] Q9NRR6 72 kDa inositol polyphosphate 5-phosphatase OS=Homo sapiens GN=INPP5E PE=1 SV=2 - [INP5E_HUMAN] P82987 ADAMTS-like protein 3 OS=Homo sapiens GN=ADAMTSL3 PE=2 SV=4 - [ATL3_HUMAN] Q9Y6K8 Adenylate kinase isoenzyme 5 OS=Homo sapiens GN=AK5 PE=1 SV=2 - [KAD5_HUMAN] P02763 Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 - [A1AG1_HUMAN] P19652 Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 - [A1AG2_HUMAN] P01011 Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 - [AACT_HUMAN] P01009 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 - [A1AT_HUMAN] P04217 Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 - [A1BG_HUMAN] P08697 Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 - [A2AP_HUMAN] P02765 Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 - [FETUA_HUMAN] P01023 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 - [A2MG_HUMAN] P01019 Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 - [ANGT_HUMAN] Q9NQ90 Anoctamin-2 OS=Homo sapiens GN=ANO2 PE=1 SV=2 - [ANO2_HUMAN] P01008 Antithrombin-III
    [Show full text]
  • MEPE Is a Novel Regulator of Growth Plate Cartilage Mineralization
    Edinburgh Research Explorer MEPE is a novel regulator of growth plate cartilage mineralization Citation for published version: Staines, K, Mackenzie, NCW, Clarkin, CE, Zelenchuk, L, Rowe, PS, MacRae, VE & Farquharson, C 2012, 'MEPE is a novel regulator of growth plate cartilage mineralization', Bone, vol. 51, no. 3, pp. 418-430. https://doi.org/10.1016/j.bone.2012.06.022 Digital Object Identifier (DOI): 10.1016/j.bone.2012.06.022 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Bone Publisher Rights Statement: Available under Open Access General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 01. Oct. 2021 Bone 51 (2012) 418–430 Contents lists available at SciVerse ScienceDirect Bone journal homepage: www.elsevier.com/locate/bone Original Full Length Article MEPE is a novel regulator of growth plate cartilage mineralization K.A. Staines a,⁎, N.C.W. Mackenzie a, C.E. Clarkin b, L. Zelenchuk c, P.S. Rowe c, V.E.
    [Show full text]
  • The Title of the Article
    Mechanism-Anchored Profiling Derived from Epigenetic Networks Predicts Outcome in Acute Lymphoblastic Leukemia Xinan Yang, PhD1, Yong Huang, MD1, James L Chen, MD1, Jianming Xie, MSc2, Xiao Sun, PhD2, Yves A Lussier, MD1,3,4§ 1Center for Biomedical Informatics and Section of Genetic Medicine, Department of Medicine, The University of Chicago, Chicago, IL 60637 USA 2State Key Laboratory of Bioelectronics, Southeast University, 210096 Nanjing, P.R.China 3The University of Chicago Cancer Research Center, and The Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL 60637 USA 4The Institute for Genomics and Systems Biology, and the Computational Institute, The University of Chicago, Chicago, IL 60637 USA §Corresponding author Email addresses: XY: [email protected] YH: [email protected] JC: [email protected] JX: [email protected] XS: [email protected] YL: [email protected] - 1 - Abstract Background Current outcome predictors based on “molecular profiling” rely on gene lists selected without consideration for their molecular mechanisms. This study was designed to demonstrate that we could learn about genes related to a specific mechanism and further use this knowledge to predict outcome in patients – a paradigm shift towards accurate “mechanism-anchored profiling”. We propose a novel algorithm, PGnet, which predicts a tripartite mechanism-anchored network associated to epigenetic regulation consisting of phenotypes, genes and mechanisms. Genes termed as GEMs in this network meet all of the following criteria: (i) they are co-expressed with genes known to be involved in the biological mechanism of interest, (ii) they are also differentially expressed between distinct phenotypes relevant to the study, and (iii) as a biomodule, genes correlate with both the mechanism and the phenotype.
    [Show full text]
  • In Silico Prediction of High-Resolution Hi-C Interaction Matrices
    ARTICLE https://doi.org/10.1038/s41467-019-13423-8 OPEN In silico prediction of high-resolution Hi-C interaction matrices Shilu Zhang1, Deborah Chasman 1, Sara Knaack1 & Sushmita Roy1,2* The three-dimensional (3D) organization of the genome plays an important role in gene regulation bringing distal sequence elements in 3D proximity to genes hundreds of kilobases away. Hi-C is a powerful genome-wide technique to study 3D genome organization. Owing to 1234567890():,; experimental costs, high resolution Hi-C datasets are limited to a few cell lines. Computa- tional prediction of Hi-C counts can offer a scalable and inexpensive approach to examine 3D genome organization across multiple cellular contexts. Here we present HiC-Reg, an approach to predict contact counts from one-dimensional regulatory signals. HiC-Reg pre- dictions identify topologically associating domains and significant interactions that are enri- ched for CCCTC-binding factor (CTCF) bidirectional motifs and interactions identified from complementary sources. CTCF and chromatin marks, especially repressive and elongation marks, are most important for HiC-Reg’s predictive performance. Taken together, HiC-Reg provides a powerful framework to generate high-resolution profiles of contact counts that can be used to study individual locus level interactions and higher-order organizational units of the genome. 1 Wisconsin Institute for Discovery, 330 North Orchard Street, Madison, WI 53715, USA. 2 Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI 53715, USA. *email: [email protected] NATURE COMMUNICATIONS | (2019) 10:5449 | https://doi.org/10.1038/s41467-019-13423-8 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13423-8 he three-dimensional (3D) organization of the genome has Results Temerged as an important component of the gene regulation HiC-Reg for predicting contact count using Random Forests.
    [Show full text]
  • The Role of Z-Disc Proteins in Myopathy and Cardiomyopathy
    International Journal of Molecular Sciences Review The Role of Z-disc Proteins in Myopathy and Cardiomyopathy Kirsty Wadmore 1,†, Amar J. Azad 1,† and Katja Gehmlich 1,2,* 1 Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK; [email protected] (K.W.); [email protected] (A.J.A.) 2 Division of Cardiovascular Medicine, Radcliffe Department of Medicine and British Heart Foundation Centre of Research Excellence Oxford, University of Oxford, Oxford OX3 9DU, UK * Correspondence: [email protected]; Tel.: +44-121-414-8259 † These authors contributed equally. Abstract: The Z-disc acts as a protein-rich structure to tether thin filament in the contractile units, the sarcomeres, of striated muscle cells. Proteins found in the Z-disc are integral for maintaining the architecture of the sarcomere. They also enable it to function as a (bio-mechanical) signalling hub. Numerous proteins interact in the Z-disc to facilitate force transduction and intracellular signalling in both cardiac and skeletal muscle. This review will focus on six key Z-disc proteins: α-actinin 2, filamin C, myopalladin, myotilin, telethonin and Z-disc alternatively spliced PDZ-motif (ZASP), which have all been linked to myopathies and cardiomyopathies. We will summarise pathogenic variants identified in the six genes coding for these proteins and look at their involvement in myopathy and cardiomyopathy. Listing the Minor Allele Frequency (MAF) of these variants in the Genome Aggregation Database (GnomAD) version 3.1 will help to critically re-evaluate pathogenicity based on variant frequency in normal population cohorts.
    [Show full text]
  • Synergistic Genetic Interactions Between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models
    BASIC RESEARCH www.jasn.org Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models Rory J. Olson,1 Katharina Hopp ,2 Harrison Wells,3 Jessica M. Smith,3 Jessica Furtado,1,4 Megan M. Constans,3 Diana L. Escobar,3 Aron M. Geurts,5 Vicente E. Torres,3 and Peter C. Harris 1,3 Due to the number of contributing authors, the affiliations are listed at the end of this article. ABSTRACT Background Autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD) are genetically distinct, with ADPKD usually caused by the genes PKD1 or PKD2 (encoding polycystin-1 and polycystin-2, respectively) and ARPKD caused by PKHD1 (encoding fibrocys- tin/polyductin [FPC]). Primary cilia have been considered central to PKD pathogenesis due to protein localization and common cystic phenotypes in syndromic ciliopathies, but their relevance is questioned in the simple PKDs. ARPKD’s mild phenotype in murine models versus in humans has hampered investi- gating its pathogenesis. Methods To study the interaction between Pkhd1 and Pkd1, including dosage effects on the phenotype, we generated digenic mouse and rat models and characterized and compared digenic, monogenic, and wild-type phenotypes. Results The genetic interaction was synergistic in both species, with digenic animals exhibiting pheno- types of rapidly progressive PKD and early lethality resembling classic ARPKD. Genetic interaction be- tween Pkhd1 and Pkd1 depended on dosage in the digenic murine models, with no significant enhancement of the monogenic phenotype until a threshold of reduced expression at the second locus was breached.
    [Show full text]
  • NPRL3 Gene NPR3 Like, GATOR1 Complex Subunit
    NPRL3 gene NPR3 like, GATOR1 complex subunit Normal Function The NPRL3 gene provides instructions for making a protein that is one piece of a group of proteins (complex) called GATOR1. This complex is found in cells throughout the body, where it regulates a signaling pathway called the mTOR pathway. The mTOR pathway is involved in cell growth and division (proliferation), the survival of cells, and the creation (synthesis) of new proteins. The role of the GATOR1 complex is to block this pathway by inhibiting (stopping) the activity of a complex called mTOR complex 1 ( mTORC1) that is integral to the mTOR pathway. In the brain, the mTOR pathway regulates many processes, including the growth and development of nerve cells and their ability to change and adapt over time (plasticity). Health Conditions Related to Genetic Changes Familial focal epilepsy with variable foci At least ten NPRL3 gene mutations have been found to cause familial focal epilepsy with variable foci (FFEVF), which is an uncommon form of recurrent seizures (epilepsy) that runs in families. Most of these mutations lead to the production of an abnormally short, nonfunctional protein. As a result, formation of normal GATOR1 complex is reduced, leading to overactivity of mTORC1 and excessive signaling of the mTOR pathway. It is not clear how an abnormally active mTOR pathway leads to the seizures of FFEVF. Research suggests that increased mTOR pathway signaling in the brain leads to changes in the connections between nerve cells (synapses) and increased activation (excitation)
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Cell, Volume 139 Supplemental Data Profiling the Human Protein-DNA
    Cell, Volume 139 Supplemental Data Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling Shaohui Hu, Zhi Xie, Akishi Onishi, Xueping Yu, Lizhi Jiang, Jimmy Lin, Hee-sool Rho, Crystal Woodard, Hong Wang, Jun-Seop Jeong, Shunyou Long, Xiaofei He, Herschel Wade, Seth Blackshaw, Jiang Qian, and Heng Zhu Supplemental Experimental Procedures Identifying Tissue-specific Motifs We developed a program to identify tissue-specific motifs. We first defined sets of tissue-specific or tissue-enriched genes by examining their gene expression profiles across multiple tissues (Yu et al., 2006). We then calculated the most over-represented single motifs (8-mers, including a wide character) in the promoters of each set of tissue-specific genes. The program then enumerated all possible combinations of the top n motifs (e.g. n = 100). For each motif pair, the program recorded the occurrence of the motif pair in the promoter sequences. We then calculated the significance score for each motif pair, which was defined as the negative logarithm of the p value, -log(p). The motif pairs with scores above a specified threshold were considered putative TF binding motif pairs in the promoter sequences. With these predicted motif pairs, we could calculate a number of partners for each motif and select a certain number of top non-redundant motifs to be tested in the protein chip experiments. Both the p values for a single motif and those for a motif pair were calculated using hypergeometric distribution. Here, we use a motif pair as an example to show the ij, procedure.
    [Show full text]
  • Genome-Wide Screen of Otosclerosis in Population Biobanks
    medRxiv preprint doi: https://doi.org/10.1101/2020.11.15.20227868; this version posted November 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Genome-wide Screen of Otosclerosis in 2 Population Biobanks: 18 Loci and Shared 3 Heritability with Skeletal Structure 4 Joel T. Rämö1, Tuomo Kiiskinen1, Juha Karjalainen1,2,3,4, Kristi Krebs5, Mitja Kurki1,2,3,4, Aki S. 5 Havulinna6, Eija Hämäläinen1, Paavo Häppölä1, Heidi Hautakangas1, FinnGen, Konrad J. 6 Karczewski1,2,3,4, Masahiro Kanai1,2,3,4, Reedik Mägi5, Priit Palta1,5, Tõnu Esko5, Andres Metspalu5, 7 Matti Pirinen1,7,8, Samuli Ripatti1,2,7, Lili Milani5, Antti Mäkitie9, Mark J. Daly1,2,3,4,10, and Aarno 8 Palotie1,2,3,4 9 1. Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of 10 Helsinki, Helsinki, Finland 11 2. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, 12 Massachusetts, USA 13 3. Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, 14 USA 15 4. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, USA 16 5. Estonian Genome Center, University of Tartu, Tartu, Estonia, Institute of Molecular and Cell Biology, 17 University of Tartu, Tartu, Estonia 18 6. Finnish Institute for Health and Welfare, Helsinki, Finland 19 7. Department of Public Health, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland 20 8.
    [Show full text]